Screener
Gilead Sciences GILD Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 79.6%+1.1pp | 79.4%+1.1pp | 78.8%+0.6pp | 78.7%+2.6pp | 78.5%+2.8pp | |
| Operating margin | -8.2%-36.1pp | 34.9%+6.3pp | 34%+28.3pp | 36.1%+33.2pp | 27.9%+18.7pp | |
| Net margin | -10.6%-32.5pp | 31%+10.2pp | 28.9%+27.2pp | 27.9%+27.4pp | 21.9%+18.1pp | |
| Returns | ||||||
| Return on equity | -20.6%-53.8pp | 43.2%+10.7pp | 40.5%+38.2pp | 40.5%+39.9pp | 33.3%+27.9pp | |
| Return on invested capital | -6.7%-24.7pp | 23.7%+4.4pp | 22.2%+19.3pp | 22.7%+21.3pp | 18%+13.7pp | |
| Efficiency | ||||||
| Asset turnover | 0.6×+0.1× | 0.5×0.0× | 0.5×0.0× | 0.5×0.0× | 0.5×0.0× | |
| Liquidity | ||||||
| Current ratio | 1.3×0.0× | 2×+0.6× | 1.6×0.0× | 1.5×+0.2× | 1.3×+0.2× | |
| Leverage | ||||||
| Debt-to-equity | 2.2×+1.0× | 0.9×-0.4× | 1.1×-0.3× | 1.2×-0.1× | 1.3×0.0× | |
| Per Share | ||||||
| Book value per share | $9.52-39.3% | $18.75+23.2% | $18.09+17.4% | $17.18+16.6% | $15.68+7.3% | |
| Valuation | ||||||
| Market capitalization | $182.89B+33.3% | $172.99B+23.8% | $152.28B+32.3% | $137.73B+31.9% | $133.35B+56.0% | |
| Price / sales | 6×+1.3× | 5.8×+1.0× | 5.2×+1.2× | 4.7×+1.0× | 4.6×+1.5× | |
| Price / book | 15.5×+9.1× | 7.4×+0.1× | 6.7×+0.8× | 6.4×+0.7× | 6.8×+2.1× | |
| Dividend yield | 2.2%-0.7pp | 2.3%-0.5pp | 2.6%-0.8pp | 2.9%-0.8pp | 3%-1.5pp |
FAQ
- What are Gilead Sciences's profit margins?
- Gilead Sciences (GILD) runs a 79.6% gross margin and a -8.2% operating margin, with a -10.6% net margin.
- Where do Gilead Sciences's ratios come from?
- Every ratio is computed from Gilead Sciences's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
